Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
AYTU BIOPHARMA, INC (AYTU)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
10-K
| Annual Report for the period ended June 30, 2023 |
| 10/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/03/2023 |
4
| PYSZCZYMUKA GREG (Chief Commercial Officer) has filed a Form 4 on AYTU BIOPHARMA, INC|
Txns:
| Exercised 208 restricted stock units
@ $0 |
|
| 09/29/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 09/27/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/15/2023 |
4
| Disbrow Jarrett (Chief Business Officer) has filed a Form 4 on AYTU BIOPHARMA, INC|
Txns:
| Granted 7,000 options to buy
@ $1.73, valued at
$12.1k
|
|
| 08/15/2023 |
4
| JAIN ABHINAV (Director) has filed a Form 4 on AYTU BIOPHARMA, INC|
Txns:
| Granted 1,500 shares
@ $0 |
|
| 08/15/2023 |
4
| LIU VIVIAN H (Director) has filed a Form 4 on AYTU BIOPHARMA, INC|
Txns:
| Granted 1,500 shares
@ $0 |
|
| 08/15/2023 |
4
| Donofrio John Jr. (Director) has filed a Form 4 on AYTU BIOPHARMA, INC|
Txns:
| Granted 1,500 shares
@ $0 |
|
| 08/15/2023 |
4
| DOCKERY CARL (Director) has filed a Form 4 on AYTU BIOPHARMA, INC|
Txns:
| Granted 1,500 shares
@ $0 |
|
| 08/15/2023 |
4
| Disbrow Joshua R. (CEO) has filed a Form 4 on AYTU BIOPHARMA, INC|
Txns:
| Granted 35,000 options to buy
@ $1.73, valued at
$60.6k
|
|
| 08/15/2023 |
4
| BROOKE CHRISTOPHER (COO) has filed a Form 4 on AYTU BIOPHARMA, INC|
Txns:
| Granted 7,000 options to buy
@ $1.73, valued at
$12.1k
|
|
| 08/15/2023 |
4
| Oki Mark K (CFO) has filed a Form 4 on AYTU BIOPHARMA, INC|
Txns:
| Granted 13,000 options to buy
@ $1.73, valued at
$22.5k
|
|
| 08/15/2023 |
4
| PYSZCZYMUKA GREG (Chief Commercial Officer) has filed a Form 4 on AYTU BIOPHARMA, INC|
Txns:
| Granted 7,000 options to buy
@ $1.73, valued at
$12.1k
|
|
| 08/15/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/06/2023 |
4
| PYSZCZYMUKA GREG (Chief Commerical Officer) has filed a Form 4 on AYTU BIOPHARMA, INC|
Txns:
| Exercised 208 restricted stock units
@ $0 |
|
| 06/16/2023 |
SC 13D/A
| Nantahala Capital Management, LLC reports a 19.7% stake in AYTU BIOPHARMA, INC. |
| 06/16/2023 |
SC 13G
| Stonepine Capital Management, LLC reports a 10% stake in Aytu BioPharma, Inc. |
| 06/12/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 06/12/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 06/09/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 06/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/06/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 06/05/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/26/2023 |
SC 13D
| Nantahala Capital Management, LLC reports a 7.2% stake in AYTU BIOPHARMA, INC. |
| 05/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
8-K
| Quarterly results |
|
|
|